Cantor Fitzgerald initiated coverage of Novavax (NVAX) with an Overweight rating and $18 price target Novavax, known for developing Nuvaxovid, a protein-based COVID-19 vaccine with Matrix-M approved in multiple geographies and the only protein-based COVID-19 vaccine available in the U.S., has shifted from a commercial model to a licensing model and seeks partnerships around novel vaccine candidates and the Matrix-M technology to generate significant upfront payments, milestones, royalties, and revenue, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax price target raised to $11 from $10 at H.C. Wainwright
- Novavax: Sell Rating Due to Declining Vaccine Demand and Financial Challenges
- Novavax Enters Lease Agreement with AstraZeneca
- Novavax announces Maryland-based locations sales for $60M
- Midday Fly By: Big banks report beats, GM takes $1.6B EV charge